By Lucas Project Foundation
For families following ALD research, a treatment announcement brings hope—and questions about who it can help.
Nezglyal, also called leriglitazone, received EU authorization on September 21, 2026. This is the authorization date, rather than the date a newsletter shared the news. EMA’s overview explains the decision.
Who is it for?
The authorization covers boys aged 2–12 with cerebral adrenoleukodystrophy (cerebral ALD) whose brain MRI lesions do not enhance with gadolinium contrast and whose neurological functional score is 0 or 1. These are specific clinical criteria; an ALD diagnosis alone does not establish eligibility. This EU authorization does not establish approval or access in other countries.
What did the study show?
EMA describes a study of 23 boys receiving Nezglyal alongside standard care, with stem cell transplantation available if eligible. There was no comparison treatment group.
At 96 weeks, or the visit before transplantation, 7 of 20 boys with sufficient data met the study’s disease-arrest outcome. Six of those seven began with non-enhancing lesions. Those findings do not predict an individual child’s outcome.
The authorization is under exceptional circumstances: evidence remains incomplete, and further safety and long-term effectiveness data are required.
What about risks?
The official product information describes fluid retention, weight gain and changes in blood-cell counts. It requires liver monitoring and lists heart failure, including a history of it, among the contraindications. Long-term safety information in children remains limited.
This is a development families can bring to their ALD team. The useful question is how the authorized population and the evidence relate to their child—not whether a headline alone changes their care.